Unity Biotechnology Stock Performance
| UBX Stock | USD 1.83 0.13 7.65% |
Unity Biotechnology holds a performance score of 11 on a scale of zero to a hundred. The entity has a beta of -0.0095, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Unity Biotechnology are expected to decrease at a much lower rate. During the bear market, Unity Biotechnology is likely to outperform the market. Use Unity Biotechnology maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Unity Biotechnology.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Unity Biotechnology are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent fundamental drivers, Unity Biotechnology showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:10 | Last Split Date 2022-10-20 |
1 | Disposition of 324 shares by Lynne Sullivan of Unity Biotechnology at 1.4 subject to Rule 16b-3 | 12/27/2024 |
2 | Insider Trading | 12/31/2024 |
3 | UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer | 01/06/2025 |
4 | Acquisition by Leonard Keith R of 25000 shares of Unity Biotechnology subject to Rule 16b-3 | 01/17/2025 |
5 | Acquisition by Anirvan Ghosh of 450000 shares of Unity Biotechnology at 2.09 subject to Rule 16b-3 | 01/22/2025 |
6 | Disposition of 642 shares by Anirvan Ghosh of Unity Biotechnology at 2.23 subject to Rule 16b-3 | 02/04/2025 |
7 | Unity Biotechnology CEO Anirvan Ghosh sells shares worth 1,431 By Investing.com - Investing.com Nigeria | 02/05/2025 |
8 | UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and ... | 03/07/2025 |
9 | UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors | 03/10/2025 |
10 | Acquisition by Nguyen Alexander Hieu of 150000 shares of Unity Biotechnology at 2.09 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 20.7 M |
Unity |
Unity Biotechnology Relative Risk vs. Return Landscape
If you would invest 100.00 in Unity Biotechnology on December 23, 2024 and sell it today you would earn a total of 83.00 from holding Unity Biotechnology or generate 83.0% return on investment over 90 days. Unity Biotechnology is generating 1.4265% of daily returns assuming volatility of 9.7348% on return distribution over 90 days investment horizon. In other words, 86% of stocks are less volatile than Unity, and above 72% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Unity Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Unity Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Unity Biotechnology, and traders can use it to determine the average amount a Unity Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1465
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | UBX | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.73 actual daily | 86 86% of assets are less volatile |
Expected Return
| 1.43 actual daily | 28 72% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Unity Biotechnology is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Unity Biotechnology by adding it to a well-diversified portfolio.
Unity Biotechnology Fundamentals Growth
Unity Stock prices reflect investors' perceptions of the future prospects and financial health of Unity Biotechnology, and Unity Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Unity Stock performance.
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 31.09 M | ||||
| Shares Outstanding | 16.87 M | ||||
| Price To Book | 4.74 X | ||||
| Price To Sales | 6.54 X | ||||
| Gross Profit | (13.01 M) | ||||
| EBITDA | (31.17 M) | ||||
| Net Income | (25.99 M) | ||||
| Cash And Equivalents | 64.51 M | ||||
| Cash Per Share | 9.26 X | ||||
| Total Debt | 19.71 M | ||||
| Debt To Equity | 1.30 % | ||||
| Current Ratio | 4.13 X | ||||
| Book Value Per Share | 0.39 X | ||||
| Cash Flow From Operations | (20.86 M) | ||||
| Earnings Per Share | (1.54) X | ||||
| Market Capitalization | 30.78 M | ||||
| Total Asset | 37.66 M | ||||
| Retained Earnings | (510.34 M) | ||||
| Working Capital | 15.01 M | ||||
About Unity Biotechnology Performance
Evaluating Unity Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Unity Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Unity Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (45.25) | (42.99) | |
| Return On Tangible Assets | (0.69) | (0.72) | |
| Return On Capital Employed | (1.10) | (1.15) | |
| Return On Assets | (0.69) | (0.72) | |
| Return On Equity | (4.00) | (3.80) |
Things to note about Unity Biotechnology performance evaluation
Checking the ongoing alerts about Unity Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Unity Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Unity Biotechnology is way too risky over 90 days horizon | |
| Unity Biotechnology may become a speculative penny stock | |
| Unity Biotechnology appears to be risky and price may revert if volatility continues | |
| Unity Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Reported Net Loss for the year was (25.99 M) with loss before taxes, overhead, and interest of (13.01 M). | |
| Unity Biotechnology has about 64.51 M in cash with (20.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from globenewswire.com: UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors |
- Analyzing Unity Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Unity Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Unity Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Unity Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Unity Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Unity Biotechnology's stock. These opinions can provide insight into Unity Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.